## Management Strategy for Wilms Tumor **Key Point:** The standard approach to localized Wilms tumor (Stage I–III) in most pediatric oncology protocols is **neoadjuvant chemotherapy followed by delayed surgery**, not immediate nephrectomy. ### Rationale for Neoadjuvant Chemotherapy 1. **Tumor downstaging** — Preoperative chemotherapy shrinks the primary tumor, making complete resection safer and reducing operative morbidity. 2. **Lymph node assessment** — Chemotherapy response helps identify involved nodes and guides postoperative staging. 3. **Protocol-driven approach** — Most pediatric oncology protocols (COG, SIOP) recommend neoadjuvant therapy for tumors >5 cm or those with unfavorable imaging features (e.g., heterogeneity, infiltration). 4. **Improved outcomes** — Neoadjuvant therapy has not compromised overall survival and reduces the need for aggressive surgery in young children. **Clinical Pearl:** In India, the COG (Children's Oncology Group) approach is increasingly adopted. A 6 cm heterogeneous mass with no metastases is a **Stage II–III candidate** — neoadjuvant chemotherapy (typically actinomycin D + vincristine ± doxorubicin) is standard before definitive surgery at 8–12 weeks. **High-Yield:** Immediate nephrectomy is reserved for: - Small, completely encapsulated Stage I tumors (<5 cm) - Intraoperative findings of rupture or spillage (then add postoperative chemotherapy) - Bilateral disease (staged separately) ### Why Not Biopsy? Percutaneous biopsy is **contraindicated** in suspected Wilms tumor — risk of tumor spillage, seeding, and upstaging. Diagnosis is made by imaging + clinical context. ### Why Not Observation? Wilms tumor is chemosensitive and curable with multimodal therapy. Observation delays definitive treatment and risks progression. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.